Saturday, 17 October 2026European Markets

CARASENT Stock 33.1% Up On Monday

Loading stream...

(VIANEWS) - The Market ended the session with CARASENT (CARA.OL) jumping 33.1% to kr19.05 on Monday while Oslo Børs Benchmark Index_GI rose 0.15% to kr1,367.92.

CARASENT's last close was kr14.30, 39.53% under its 52-week high of kr23.65.

About CARASENT

Carasent ASA provides cloud based electronic health record solutions to the health care industry in Sweden, Norway, and internationally. The company offers Webdoc, a cloud-based EHR system; Metodika EPM, a solution designed for mid-to-large-sized organizations; Medrave M4 to give healthcare staff and managers an overview and clear picture of the patient group being treated; Health Profile Institute AB (HPI), an occupational care platform; Ad Curis, a record system with digital services tailored for the specialist healthcare service with clients in rehabilitation, interdisciplinary specialized drug treatment, and mental health care, as well as businesses in care and prevention; and Ad Opus, a journal system for follow-up of participants in measures. It also provides platform services, such as Vårdrummet, Confrere, Ad Voca, electronic letters, SMS services, portal to medical services, and consulting and other services. The company was formerly known as Apptix ASA and changed its name to Carasent ASA in May 2019. Carasent ASA was founded in 1997 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, CARASENT has a trailing twelve months EPS of kr-0.6.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -4.05%.

Moving Average

CARASENT's value is way higher than its 50-day moving average of kr15.55 and way above its 200-day moving average of kr16.10.

Yearly Top and Bottom Value

CARASENT's stock is valued at kr19.05 at 22:32 EST, way below its 52-week high of kr23.65 and way above its 52-week low of kr13.50.

More news about CARASENT (CARA.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Governance Reshuffle: CEO Successions, Activist Settlements and Corporate Separations
Across sectors, boards are replacing or rotating leadership (Bausch + Lomb's abrupt CEO exit, Keyser's move to advisor, Deputy CEO promotions, Brown-Forman and BellRing successions). At the same time, activist pressure is being settled through cooperation agreements and board seats (Stride/Fivespan, Al Shams) and through structural separations (National Fuel's IUG spin-out, NGEx). The common thread is boards using governance levers such as new committees, advisory seats and planned succession to reset capital allocation and strategy. Public messaging stresses continuity and partnership, but the number of interim appointments and activist-driven changes points to underlying pressure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,384 source documents archived
Query this data → isubstrate.com